Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition that affects around ...

Pfizer has picked up approval in the EU for Litfulo, its JAK inhibitor for severe alopecia areata, extending its challenge to Eli Lilly’s first-to-market Olumiant. The European Commission has ...

Called Ritlecitinib or Litfulo, it could help thousands of ... the drug helps fight inflammation to improve hair growth. Alopecia areata is an autoimmune disease where the body's immune system ...

Since then, Tisdale — who has partnered with Pfizer and Litfulo, an FDA-approved pill for people 12 and older with severe alopecia areata — tells PEOPLE in an exclusive interview that she has ...

LAS VEGAS, NV, UNITED STATES, January 15, 2025 /EINPresswire / -- The Alopecia Areata market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period.